Objective
Accumulation of toxic aggregation-prone protein into inclusions and aggregates is the hallmark of most neurodegenerative diseases, a broad class of disorders including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and polyglutamine diseases. In this proposal, using SBMA as a model of neurodegenerative polyglutamine-related disorder, we intend to move a step forward expanding knowledge of the neurodegeneration. In particular, we will provide a suitable model system such as differentiated iPSCs from SBMA patients to study molecular mechanism and to find out potential therapeutic drugs for neurodegenerative diseases. To define the disease-phenotype of differentiated iPS cells we will take advantage of specific features of SBMA disorders: the ligand-dependent toxicity of expanded AR. The ligand binding induces many modifications of AR protein such as phosphorylation. Since phosphorylation of mutant AR is an important determinant of SBMA pathogenesis, we will also characterize the impact of cyclic adenosine monophosphatate (cAMP)-dependent protein kinase A (PKA) signaling on the mutant AR toxicity. Then, we will use this information to identify agents that promote such modifications to find out potential therapy. Therefore, in order to develop treatment for SBMA, we will test the effect of neuropeptides that stimulates the generation of cAMP and activation of PKA, to target SBMA spinal cord.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences clinical medicine oncology prostate cancer
- medical and health sciences basic medicine neurology neurodegenerative diseases dementia alzheimer
- natural sciences biological sciences biochemistry biomolecules proteins
- medical and health sciences basic medicine neurology neurodegenerative diseases parkinson
- medical and health sciences basic medicine neurology amyotrophic lateral sclerosis
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP7-PEOPLE-2011-IOF
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
16163 Genova
Italy
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.